{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:13:53Z","timestamp":1778321633431,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.3816\/clm.2005.n.045","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:34Z","timestamp":1221095434000},"page":"181-190","source":"Crossref","is-referenced-by-count":29,"title":["New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals"],"prefix":"10.3816","volume":"6","author":[{"given":"Brian G.M.","family":"Durie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2005.n.045_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2003.03902.x","article-title":"Thalidomide in multiple myeloma: current status and future prospects. UK Myeloma Forum and the BCSH Haematology\/Oncology Task Forces","volume":"120","author":"Cavenagh","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib2","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cells dyscrasias with thalidomide and its derivatives","volume":"23","author":"Dimopoulos","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib3","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2005.n.045_bib4","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2005.n.045_bib5","first-page":"63a","article-title":"A prospective randomized trial of oral Melphalan, prednisone, thalidomide (MPT) v oral Melphalan, prednisone (MP): an interim analysis","volume":"104","author":"Palumbo","year":"2005","journal-title":"Blood"},{"issue":"suppl 2","key":"10.3816\/CLM.2005.n.045_bib6","first-page":"158","article-title":"A prospective randomized trial of oral Melphalan, prednisone, thalidomide (MPT) vs oral Melphalan, prednisone (MP): an interim analysis. 10th Congress of the European Hematology Association","volume":"90","author":"Gokbuget","year":"2005","journal-title":"Hematol J"},{"issue":"suppl 2","key":"10.3816\/CLM.2005.n.045_bib7","first-page":"158","article-title":"Thalidomide-dexamethasone versus melphalan-prednisone as first line treatment in elderly patients with multiple myeloma: an interim analysis. 10th Congress of the European Hematology Association","volume":"90","author":"Wassmann","year":"2005","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2005.n.045_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(80)92941-4","article-title":"Reappraisal of plateau phase in myeloma","volume":"2","author":"Durie","year":"1980","journal-title":"Lancet"},{"key":"10.3816\/CLM.2005.n.045_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"New Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib13","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone of with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib15","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib16","doi-asserted-by":"crossref","first-page":"98a","DOI":"10.1182\/blood.V104.11.331.331","article-title":"Combination therapy with CC- 5013 (lenalidoide; Revlimd) plus dexamethasone (Rev\/Dex) for newly diag- nosed myeloma (MM)","volume":"104","author":"Rajkumar","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS- 341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloms","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib20","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation [published erratum in Hematol J 2004; 5:285]","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2005.n.045_bib22","first-page":"52","article-title":"Cost Effectiveness of Bortezomib in the Treatment of Advanced Multiple Myeloma","volume":"17","author":"Mehta","year":"2004","journal-title":"Manage Care Interface"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.045_bib23","first-page":"S181","article-title":"Interactive computer program reveals current disease features and patterns of myeloma management. The Hematology Journal 9th International Workshop","volume":"4","author":"Durie","year":"2003","journal-title":"Hem J"},{"key":"10.3816\/CLM.2005.n.045_bib24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report to the International Myeloma Working Group","volume":"121","author":"The International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2005-04-1451","article-title":"Multiple myeloma: the death of VAD as initial therapy","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vicristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","article-title":"Impact of complete remission intensive therapy in patients with responsive multiple myeloma","volume":"27","author":"Alexanian","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2005.n.045_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2141.2002.03231.x","article-title":"Predicting long-term (> or 5 =years) eventfree survival in multiple myeloma patients following planned tandem autotransplants","volume":"116","author":"Tricot","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.bmt.1704313","article-title":"High-dose therapy\/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission","volume":"33","author":"Nadal","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2005.n.045_bib30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1046\/j.1365-2141.2001.02530.x","article-title":"The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma","volume":"112","author":"Davies","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2141.2000.02012.x","article-title":"Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients","volume":"109","author":"Lahuerta","year":"2000","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib32","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloblative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib33","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and 17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib34","doi-asserted-by":"crossref","unstructured":"Jagannath S, Richardson PG, et al. Bortezomib to overcome the poor prognostic impact of chromosome 13 deletion in phase 2 and 3 clinical studies. Hem J, 10th Congress of the Eur Hem Assoc 2005; 90(s2). Supplement 0620.","DOI":"10.1200\/jco.2005.23.16_suppl.6501"},{"key":"10.3816\/CLM.2005.n.045_bib35","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1200\/JCO.2004.05.111","article-title":"Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials","volume":"22","author":"Durie","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(03)01077-5","article-title":"Management of multiple myeloma: a systemic review and critical appraisal of published studies","volume":"4","author":"Kumar","year":"2003","journal-title":"Lancet"},{"key":"10.3816\/CLM.2005.n.045_bib37","doi-asserted-by":"crossref","first-page":"778a","DOI":"10.1182\/blood.V104.11.2847.2847","article-title":"Treatment with AMD3100 combined with standard doses of G-CSF leads to rapid, consistent mobilization of hematopoietic progenitor cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma","volume":"104","author":"Stiff","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib38","doi-asserted-by":"crossref","first-page":"156a","DOI":"10.1182\/blood.V104.11.156.156","volume":"104","author":"Crowley","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib39","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.3816\/CLM.2005.n.045_bib40","first-page":"S103","article-title":"Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: an update with additional follow-up","volume":"5","author":"Richardson","year":"2005","journal-title":"Haematol J"},{"key":"10.3816\/CLM.2005.n.045_bib41","first-page":"265a","article-title":"CR may not be a good prognostic indicator of ultimate outcome. The 1-year landmark was chosen because the large majority of CR patients for CR patients versus 37% for no Cr patients (i.e., PR and <PR)","volume":"104","author":"Tricot","year":"2004","journal-title":"Blood"},{"issue":"16 suppl","key":"10.3816\/CLM.2005.n.045_bib42","first-page":"560s","article-title":"Results of total therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM)","volume":"23","author":"Barlogie","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib43","first-page":"62a","article-title":"Randomized clinical trial comparing Melphalan-prednisone (MP), MP-Thalidomide (MP-THAL) and high-dose therapy using Melphalan 100 MG\/M2 (MEL100) for newly diagnosed myeloma patients aged 65-75 years, interim analysis of the IFM 99-06 trial on 350 patients","volume":"104","author":"Facon","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib44","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification versus continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group Pethema","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V104.11.333.333","article-title":"A phase 2 study of bortezomib as firstline therapy in patients with multiple myeloma","volume":"104","author":"Jagannath","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib46","doi-asserted-by":"crossref","first-page":"416a","DOI":"10.1182\/blood.V104.11.1490.1490","article-title":"Bortezomib (Velcade,) plus dexamethasone as induction treatment prior to autologous stem cell -transplantation in patients with newly diagnosed multiple myeloma primary results of an IFM phase II study","volume":"104","author":"Harousseau","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib47","first-page":"64a","article-title":"VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma","volume":"104","author":"Alexanian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib48","doi-asserted-by":"crossref","first-page":"943a","DOI":"10.1182\/blood.V104.11.3462.3462","article-title":"A phase I\/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients","volume":"104","author":"Mateos","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib49","doi-asserted-by":"crossref","first-page":"100a","DOI":"10.1182\/blood.V104.11.336.336","article-title":"Phase II trial of single agent bortezomib (Velcade,) in patients with previously untreated multiple myeloma (MM)","volume":"104","author":"Richardson","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib50","first-page":"271a","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM","volume":"104","author":"Hundemer","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.045_bib51","first-page":"S59","article-title":"Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma","volume":"4","author":"Fermand","year":"2003","journal-title":"Hematol J"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.045_bib52","first-page":"560","article-title":"Single versus tandem autologous transplants in multiple myeloma: Italian experience","volume":"4","author":"Cavo","year":"2003","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2005.n.045_bib53","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1997.15.4.1672","article-title":"Patient preferences for interferon Alfa in multiple myeloma","volume":"15","author":"Ludwig","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.045_bib54","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.V61.5.929.929","article-title":"Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics and patient survival duration","volume":"61","author":"Durie","year":"1983","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.1984.tb02909.x","article-title":"Is myeloma really a monoclonal disease?","volume":"57","author":"Durie","year":"1984","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2141.1984.tb06116.x","article-title":"Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS) smoldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy","volume":"58","author":"Boccadoro","year":"1984","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.045_bib57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.V58.3.471.471","article-title":"Drug resistance in multiple myeloma associated with high in vitro incorporation of 3(H)-Thymidine","volume":"58","author":"Hofmann","year":"1981","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V66.3.548.548","article-title":"Establishment of two new myeloma cell lines from bilateral pleural effusions: evidence for sequential in vivo clonal change","volume":"66","author":"Durie","year":"1985","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.V66.1.229.229","article-title":"CALLA-positive myeloma: an aggressive subtype with poor survival","volume":"66","author":"Durie","year":"1985","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib60","first-page":"679a","article-title":"Multiple myeloma stem cells and plasma cells display distinct drug sensitivities","volume":"104","author":"Matsui","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib61","first-page":"1457","article-title":"Whole-Body F-FDG PET identifies high-risk myeloma","volume":"43","author":"Durie","year":"2002","journal-title":"J Nucl Med"},{"key":"10.3816\/CLM.2005.n.045_bib62","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM199801153380307","article-title":"Protective and damaging effects of stress mediators","volume":"338","author":"McEwen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nri1571","article-title":"Stress-induced immune dysfunction: implications for health","volume":"5","author":"Glaser","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.3816\/CLM.2005.n.045_bib65","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1073\/pnas.1531903100","article-title":"Chronic stress and age-related increases in the proinflammtory cytokine IL-6","volume":"100","author":"Kiecolt-Glaser","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2005.n.045_bib66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/jaut.1996.0026","article-title":"T cell mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases","volume":"9","author":"Sakaguchi","year":"1996","journal-title":"J Autoimm"},{"key":"10.3816\/CLM.2005.n.045_bib67","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.1993.01820210015002","article-title":"Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later","volume":"50","author":"Fawzy","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.3816\/CLM.2005.n.045_bib68","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.045_bib69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.1974.03240070065040","article-title":"Thoughts on cancer chemotherapy and combination modality therapy","volume":"230","author":"Skipper","year":"1974","journal-title":"JAMA"},{"key":"10.3816\/CLM.2005.n.045_bib70","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10428199809059231","article-title":"The expression of T cell related costimulatory molecules in multiple myeloma","volume":"31","author":"Brown","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2005.n.045_bib71","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal, but functionality defective as they fail to up regulate CD80 (B7-1) expression after huCD40LT stimulation due to inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.045_bib72","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1200\/JCO.2005.17.129","article-title":"Clinical outcomes in the (4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance","volume":"23","author":"Jaksic","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:45Z","timestamp":1588918185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1557919011703912"],"URL":"https:\/\/doi.org\/10.3816\/clm.2005.n.045","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}